1. Impact of COVID-19 on Alzheimer’s Disease Risk: Viewpoint for Research Action. Healthcare (Basel). 2020 Aug 21;8(3):E286.
         Abate G, Memo M, Uberti D.
  2. A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensemble and on multivariate algorithms, to characterize late onset Alzheimer’s disease. Sci Rep. 2020 Jul                 21;10(1):12063
         Squillario M, Abate G, Tomasi F, Tozzo V, Barla A, Uberti D; Alzheimer’s Disease Neuroimaging Initiative ADNI).
  3. Electrochemical detection of different p53 conformations by using nanostructured surfaces. Sci Rep. 2019 Nov 22;9(1):17347
     Tonello S, Stradolini F, Abate G, Uberti D, Serpelloni M, Carrara S, Sardini E.
  4. Focusing on Alzheimer’s Disease. Oxid Med Cell Longev. 2017;2017:7039816.
    Abate G, Marziano M, Rungratanawanich W, Memo M, Uberti D. Nutrition and AGE-ing:
  5. Comparison of Extracellular and Intracellular Blood Compartments Highlights Redox Alterations in Alzheimer’s and Mild Cognitive Impairment Patients. Curr Alzheimer Res.                 2017;14(1):112-122.
     Arce-Varas N, Abate G, Prandelli C, Martínez C, Cuetos F, Menéndez M, Marziano M, Cabrera-García D, Fernández-Sánchez MT, Novelli A, Memo M, Uberti D.
  6. Dietary zeolite supplementation reduces oxidative damage and plaque generation in the brain of an Alzheimer’s disease mouse model. Life Sci. 2013 May 20;92(17-19):903-10.
     Montinaro M, Uberti D, Maccarinelli G, Bonini SA, Ferrari-Toninelli G, Memo M.
  7. Zyxin is a novel target for β-amyloid peptide: characterization of its role in Alzheimer’s pathogenesis. J Neurochem. 2013 Jun;125(5):790-9.
     Lanni C, Necchi D, Pinto A, Buoso E, Buizza L, Memo M, Uberti D, Govoni S, Racchi M.
  8. Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth- associated protein 43 expression. Cell Death Dis. 2013 Feb 7;4(2):e484
    Buizza L, Prandelli C, Bonini SA, Delbarba A, Cenini G, Lanni C, Buoso E, Racchi M, Govoni S, Memo M, Uberti D..
  9. Crosstalk between the ubiquitin-proteasome system and autophagy in a human cellular model of Alzheimer’s disease. Biochim Biophys Acta. 2012 Nov;1822(11):1741-51.
    Cecarini V, Bonfili L, Cuccioloni M, Mozzicafreddo M, Rossi G, Buizza L, Uberti D, Angeletti M, Eleuteri AM.
  10. p53 at the crossroads between cancer and neurodegeneration. Free Radic Biol Med. 2012 May 1;52(9):1727-33.
    Lanni C, Racchi M, Memo M, Govoni S, Uberti D.
  11. Highly pathogenic Alzheimer’s disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes. J        Alzheimers Dis. 2012;32(2):397-415.
    Bialopiotrowicz E, Szybinska A, Kuzniewska B, Buizza L, Uberti D, Kuznicki J, Wojda U.
  12. Butterfield DA, Memo M, Uberti D. Conformational altered p53 as an early marker of oxidative stress
     Buizza L, Cenini G, Lanni C, Ferrari-Toninelli G, Prandelli C, Govoni S, Buoso E, Racchi M, Barcikowska M, Styczynska M, Szybinska A, in Alzheimer’s disease. PLoS One.                        2012;7(1):e29789.
  13. Unfolded p53 in the pathogenesis of Alzheimer’s disease: is HIPK2 the link? Aging (Albany NY). 2010 Sep;2(9):545-54.
    Stanga S, Lanni C, Govoni S, Uberti D, D’Orazi G, Racchi M.
  14. Homeodomain interacting protein kinase 2: a target for Alzheimer’s beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS One. 2010 Apr 14;5(4):e10171.
    Lanni C, Nardinocchi L, Puca R, Stanga S, Uberti D, Memo M, Govoni S, D’Orazi G, Racchi M.
  15. Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane. J Mol Med (Berl). 2010 Jun;88(6):597-608.
    Zampagni M, Evangelisti E, Cascella R, Liguri G, Becatti M, Pensalfini A, Uberti D, Cenini G, Memo M, Bagnoli S, Nacmias B, Sorbi S, Cecchi C.
  16. Wild type but not mutant APP is involved in protective adaptive responses against oxidants. Amino Acids. 2010 Jun;39(1):271-83.
    Cenini G, Maccarinelli G, Lanni C, Bonini SA, Ferrari-Toninelli G, Govoni S, Racchi M, Butterfield DA, Memo M, Uberti D.
  17. Increased CD44 gene expression in lymphocytes derived from Alzheimer disease patients. Neurodegener Dis. 2010;7(1-3):143-7.
    Uberti D, Cenini G, Bonini SA, Barcikowska M, Styczynska M, Szybinska A, Memo M.
  18. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis. 2010;20(1):97-104.
    Lanni C, Racchi M, Stanga S, Mazzini G, Ranzenigo A, Polotti R, Memo M, Govoni S, Uberti D.
  19. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways. Amino Acids. 2010 Apr;38(4):1101-6.
    Cenini G, Cecchi C, Pensalfini A, Bonini SA, Ferrari-Toninelli G, Liguri G, Memo M, Uberti D.
  20. Glutathionylation of the pro-apoptotic protein p53 in Alzheimer’s disease brain: implications for AD pathogenesis. Neurochem Res. 2009 Apr;34(4):727-33.
    Di Domenico F, Cenini G, Sultana R, Perluigi M, Uberti D, Memo M, Butterfield DA.
  21. Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53. Cancer Immunol Immunother. 2009 Dec;58(12):1909-17.
    Salvioli S, Capri M, Bucci L, Lanni C, Racchi M, Uberti D, Memo M, Mari D, Govoni S, Franceschi C.
  22. G. Alzheimer’s disease: new diagnostic and therapeutic tools. Immun Ageing. 2008 Aug 13;5:7.
    Racchi M, Uberti D, Govoni S, Memo M, Lanni C, Vasto S, Candore G, Caruso C, Romeo L, Scapagnini
  23. Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: focus on p53. Curr Pharm Des. 2008;14(26):2665-71.
    Lanni C, Racchi M, Uberti D, Mazzini G, Stanga S, Sinforiani E, Memo M, Govoni S.
  24. A putative peripheral marker for Alzheimer’s disease. Neurodegener Dis. 2008;5(3-4):209-11.
    Uberti D, Lanni C, Racchi M, Govoni S, Memo M. Conformationally altered p53:
  25. Conformationally altered p53: a novel Alzheimer’s disease marker? Mol Psychiatry. 2008 Jun;13(6):641-7.
    Lanni C, Racchi M, Mazzini G, Ranzenigo A, Polotti R, Sinforiani E, Olivari L, Barcikowska M, Styczynska M, Kuznicki J, Szybinska A, Govoni S, Memo M, Uberti D.
  26. Unfolded p53: a potential biomarker for Alzheimer’s disease. J Alzheimers Dis. 2007 Aug;12(1):93-9.
    Lanni C, Uberti D, Racchi M, Govoni S, Memo M.
  27. Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem. 2007 Oct;103(1):322-33.
    Uberti D, Cenini G, Olivari L, Ferrari-Toninelli G, Porrello E, Cecchi C, Pensalfini A, Liguri G, Govoni S, Racchi M, Maurizio M.
  28. Pramipexole prevents neurotoxicity induced by oligomers of beta-amyloid. Eur J Pharmacol. 2007 Aug 27;569(3):194-6.
    Uberti D, Bianchi I, Olivari L, Ferrari-Toninelli G, Canonico P, Memo M.
  29. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology. 2007 Apr;32(4):872-80.
    Uberti D, Ferrari-Toninelli G, Bonini SA, Sarnico I, Benarese M, Pizzi M, Benussi L, Ghidoni R, Binetti G, Spano P, Facchetti F, Memo M.
  30. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer’s disease patients. Neurobiol Aging. 2006 Sep;27(9):1193-201.
    Uberti D, Lanni C, Carsana T, Francisconi S, Missale C, Racchi M, Govoni S, Memo M.
  31. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death Differ. 2004 Sep;11(9):962-73.
    Bonafé M, Salvioli S, Barbi C, Trapassi C, Tocco F, Storci G, Invidia L, Vannini I, Rossi M, Marzi E, Mishto M, Capri M, Olivieri F, Antonicelli R, Memo M, Uberti D, Nacmias B, Sorbi S, Monti D, Franceschi C.
  32. Nerve growth factor restores p53 function in pituitary tumor cell lines via trkA-mediated activation of phosphatidylinositol 3-kinase. Mol Endocrinol. 2004 Jan;18(1):162-72.
    Facchetti M, Uberti D, Memo M, Missale C.
  33. Alzheimer’s disease linking neurodegeneration with neurodevelopment. Funct Neurol. 2003 Jul- Sep;18(3):145-8
    Grilli M, Ferrari Toninelli G, Uberti D, Spano P, Memo M.
  34. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer’s disease patients. J Cell Sci. 2002 Aug 1;115(Pt 15):3131-8.
    Uberti D, Carsana T, Bernardi E, Rodella L, Grigolato P, Lanni C, Racchi M, Govoni S, Memo M.
  35. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12822-7.
    Grilli M, Diodato E, Lozza G, Brusa R, Casarini M, Uberti D, Rozmahel R, Westaway D, St George-Hyslop P, Memo M, Ongini E.
  36. Contribution of NF-kappaB and p53 in the glutamate-induced apoptosis. Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):447-54.
    Uberti D, Grilli M, Memo M.
  37. Induction of p53 in the glutamate-induced cell death program. Amino Acids. 2000;19(1):253-61.
    Uberti D, Grilli M, Memo M.
  38. Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. Brain Res Mol Brain Res. 1999 Mar 5;65(2):167-75.
    Uberti D, Yavin E, Gil S, Ayasola KR, Goldfinger N, Rotter V.
  39. Induction of tumour- suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurons triggered by excitatory amino acids. Eur J Neurosci. 1998 Jan;10(1):246-54.
    Uberti D, Belloni M, Grilli M, Spano P, Memo M.